Soligenix announces publication demonstrating positive correlates of protection with rivax® in non-human primate survival after ricin challenge

Rivax ® - vaccinated nhp survival was statistically significantly correlated with an epitope-specific serum assay ("epicc") prior to challenge correlates of protection are essential to support approval via the fda "animal rule" princeton, n.j. , dec. 20, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of preclinical immunogenicity challenge studies for rivax® (heat stable ricin toxin vaccine) demonstrating statistically significant correlates of protection predicting survival after lethal aerosolized ricin challenge in non-human primates (nhps).
SNGX Ratings Summary
SNGX Quant Ranking